Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

"Neural Killer" Cells: Autologous Cytotoxic Neural Stem Cells for Fighting Glioma.

Mutukula N, Elkabetz Y.

Cell Stem Cell. 2017 Apr 6;20(4):426-428. doi: 10.1016/j.stem.2017.03.019.

2.

Tumor-homing cytotoxic human induced neural stem cells for cancer therapy.

Bagó JR, Okolie O, Dumitru R, Ewend MG, Parker JS, Werff RV, Underhill TM, Schmid RS, Miller CR, Hingtgen SD.

Sci Transl Med. 2017 Feb 1;9(375). pii: eaah6510. doi: 10.1126/scitranslmed.aah6510.

PMID:
28148846
3.

Stem cells and the origin of different glioma subtypes.

Roesler R.

J Neurosurg. 2014 Apr;120(4):1009-10. doi: 10.3171/2013.10.JNS132205. Epub 2014 Feb 7. No abstract available.

PMID:
24506242
4.

Stem cells and the origin of different glioma subtypes. Response.

Tamura K, Aoyagi M.

J Neurosurg. 2014 Apr;120(4):1010-1. No abstract available.

PMID:
24809083
5.

CD133-positive stem cells.

Bian EB, Li J, Zhao B.

J Neurosurg. 2014 Apr;120(4):1011-2. doi: 10.3171/2013.10.JNS132261. Epub 2014 Feb 7. No abstract available.

PMID:
24506246
6.

CD133-positive stem cells. Response.

Tamura K, Aoyagi M.

J Neurosurg. 2014 Apr;120(4):1012. No abstract available.

PMID:
24809085
7.

HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells.

Wolpert F, Roth P, Lamszus K, Tabatabai G, Weller M, Eisele G.

J Neuroimmunol. 2012 Sep 15;250(1-2):27-34. doi: 10.1016/j.jneuroim.2012.05.010. Epub 2012 Jun 9.

PMID:
22688424
8.

Glioma stem cell research for the development of immunotherapy.

Xu Q, Yuan X, Yu JS.

Adv Exp Med Biol. 2012;746:216-25. doi: 10.1007/978-1-4614-3146-6_17. Review.

PMID:
22639171
9.

Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients.

Crane CA, Austgen K, Haberthur K, Hofmann C, Moyes KW, Avanesyan L, Fong L, Campbell MJ, Cooper S, Oakes SA, Parsa AT, Lanier LL.

Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12823-8. doi: 10.1073/pnas.1413933111. Epub 2014 Aug 18.

10.

Immune defects observed in patients with primary malignant brain tumors.

Dix AR, Brooks WH, Roszman TL, Morford LA.

J Neuroimmunol. 1999 Dec;100(1-2):216-32. Review.

PMID:
10695732
11.

The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.

Huang BY, Zhan YP, Zong WJ, Yu CJ, Li JF, Qu YM, Han S.

PLoS One. 2015 Aug 12;10(8):e0134715. doi: 10.1371/journal.pone.0134715. eCollection 2015.

12.

Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.

Lemke D, Pfenning PN, Sahm F, Klein AC, Kempf T, Warnken U, Schnölzer M, Tudoran R, Weller M, Platten M, Wick W.

Clin Cancer Res. 2012 Jan 1;18(1):105-17. doi: 10.1158/1078-0432.CCR-11-0880. Epub 2011 Nov 11.

13.

Growth hormone enhances natural killer cell activity against glioma.

Shimizu K, Adachi K, Teramoto A.

J Nippon Med Sch. 2005 Dec;72(6):335-40.

14.
15.

[Effects of interferons on syngeneic murine malignant glioma-specific killer T cell].

Yamasaki T, Yamashita J, Handa H, Namda Y, Hanaoka M.

No Shinkei Geka. 1983 Oct;11(10):1059-67. Japanese.

PMID:
6196674
16.

Cytotoxic activity of allogeneic natural killer cells on U251 glioma cells in vitro.

Guo M, Wu T, Wan L.

Mol Med Rep. 2016 Jul;14(1):583-9. doi: 10.3892/mmr.2016.5220. Epub 2016 May 6.

PMID:
27175912
17.

Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet.

Lussier DM, Woolf EC, Johnson JL, Brooks KS, Blattman JN, Scheck AC.

BMC Cancer. 2016 May 13;16:310. doi: 10.1186/s12885-016-2337-7.

18.

Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy.

Wu A, Wiesner S, Xiao J, Ericson K, Chen W, Hall WA, Low WC, Ohlfest JR.

J Neurooncol. 2007 Jun;83(2):121-31. Epub 2006 Nov 1. Erratum in: J Neurooncol. 2007 Jun;83(2):133.

PMID:
17077937
19.
20.

Particular features of cell-mediated immunity in patients with anaplastic gliomas. A comparison with kidney and bladder cancer patients.

Servadei F, Parente R, Bucci M, Beltrandi E, Tognetti F, Gaist G.

J Neurooncol. 1983;1(4):327-32.

PMID:
6088720

Supplemental Content

Support Center